POET Stock: $430M Cash Piles Up - Buy or Avoid?

POET has rebranded itself around photonics and an "Optical Interposer" that promises to move light, not electrons, through AI data centers, and the company says it's finally shifting from years of R&D to commercial production ($POET). They report initial production orders and a clear ramp plan, and they’ve fortified the balance sheet with fresh financing to give the team time to scale. Still, the business is tiny today, has a long history of pivots, and faces brutal execution risk, fierce competitors, and skeptics who have targeted the stock. Is this a genuine breakout for a game-changing component supplier, or another speculative bet that stumbles before it ever reaches scale?This podcast is for informational and educational purposes only. Information may not be complete or accurate. It does not constitute financial, investment, legal, or other professional advice. Always do your own research and consult with a licensed financial advisor.And don't forget, you can suggest the tickers you're interested in at www.the5minuteticker.com.